James W. Ironside

James W. Ironside

Auto-generated profile, based on publicly available information

James W. Ironside

National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1996 in The Lancet
Verified
Journal Article
Closed access
RWR.G Will
R.G Will
JIJ.W Ironside
J.W Ironside
MZM Zeidler
M Zeidler
KEK Estibeiro
K Estibeiro
SCS.N Cousens
S.N Cousens
AHA Hofman
A Hofman

2 October 1997 in Nature
Verified
Journal Article
Closed access
PDF file
MBM. E. Bruce
M. E. Bruce
RWR. G. Will
R. G. Will
JIJ. W. Ironside
J. W. Ironside
IMI. McConnell
I. McConnell
DDD. Drummond
D. Drummond
CBC. J. Bostock
C. J. Bostock

24 October 1996 in Nature
Verified
Journal Article
Closed access
PDF file
JCJohn Collinge
John Collinge
KSKatie C. L. Sidle
Katie C. L. Sidle
JMJulie Meads
Julie Meads
JIJames Ironside
James Ironside
AHAndrew Hill
Andrew Hill

1 August 2004 in The Lancet
Verified
Journal Article
Closed access
APAlexander H Peden
Alexander H Peden
MHMark W Head
Mark W Head
LDL Ritchie Diane
L Ritchie Diane
EJE Bell Jeanne
E Bell Jeanne
WJW Ironside James
W Ironside James

27 March 2015 in Alzheimer's & Dementia
Verified
Journal Article
Open access
OSOsama Sabri
Osama Sabri
MSMarwan N. Sabbagh
Marwan N. Sabbagh
JSJohn Seibyl
John Seibyl
HBHenryk Barthel
Henryk Barthel
HAHiroyasu Akatsu
Hiroyasu Akatsu
FGFlorbetaben Phase 3 Study Group
Florbetaben Phase 3 Study Group
Background: Evaluation of brain β‐amyloid by positron emission tomography (PET) imaging can assist in the diagnosis of Alzheimer disease (AD) and other dementias.Methods: Open‐label, nonrandomized, multicenter, phase 3 study to validate the 18F‐labeled β‐amyloid tracer florbetaben by comparing in vivo PET imaging with post‐mortem histopathology.Results: Brain images and tissue from 74 deceased subjects (of 216 trial participants) were analyzed. Forty‐six of 47 neuritic β‐amyloid‐positive cases were read as PET positive, and 24 of 27 neuritic β‐amyloid plaque‐negative cases were read as PET negative (sensitivity 97.9% [95% confidence interval or CI 93.8–100%], specificity 88.9% [95% CI 77.0–100%]). In a subgroup, a regional tissue‐scan matched analysis was performed. In areas known to strongly accumulate β‐amyloid plaques, sensitivity and specificity were 82% to 90%, and 86% to 95%, respectively.Conclusions: Florbetaben PET shows high sensitivity and specificity for the detection of histopathology‐confirmed neuritic β‐amyloid plaques and may thus be a valuable adjunct to clinical diagnosis, particularly for the exclusion of AD.Trial registration: ClinicalTrials.gov NCT01020838.

10 December 2015 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
Gabor G. KovacsGabor G. Kovacs
Gabor G. Kovacs
IFIsidro Ferrer
Isidro Ferrer
LGLea T. Grinberg
Lea T. Grinberg
IAIrina Alafuzoff
Irina Alafuzoff
JAJohannes Attems
Johannes Attems
DDDennis W. Dickson
Dennis W. Dickson
Pathological accumulation of abnormally phosphorylated tau protein in astrocytes is a frequent, but poorly characterized feature of the aging brain. Its etiology is uncertain, but its presence is sufficiently ubiquitous to merit further characterization and classification, which may stimulate clinicopathological studies and research into its pathobiology. This paper aims to harmonize evaluation and nomenclature of aging-related tau astrogliopathy (ARTAG), a term that refers to a morphological spectrum of astroglial pathology detected by tau immunohistochemistry, especially with phosphorylation-dependent and 4R isoform-specific antibodies. ARTAG occurs mainly, but not exclusively, in individuals over 60 years of age. Tau-immunoreactive astrocytes in ARTAG include thorn-shaped astrocytes at the glia limitans and in white matter, as well as solitary or clustered astrocytes with perinuclear cytoplasmic tau immunoreactivity that extends into the astroglial processes as fine fibrillar or granular immunopositivity, typically in gray matter. Various forms of ARTAG may coexist in the same brain and might reflect different pathogenic processes. Based on morphology and anatomical distribution, ARTAG can be distinguished from primary tauopathies, but may be concurrent with primary tauopathies or other disorders. We recommend four steps for evaluation of ARTAG: (1) identification of five types based on the location of either morphologies of tau astrogliopathy: subpial, subependymal, perivascular, white matter, gray matter; (2) documentation of the regional involvement: medial temporal lobe, lobar (frontal, parietal, occipital, lateral temporal), subcortical, brainstem; (3) documentation of the severity of tau astrogliopathy; and (4) description of subregional involvement. Some types of ARTAG may underlie neurological symptoms; however, the clinical significance of ARTAG is currently uncertain and awaits further studies. The goal of this proposal is to raise awareness of astroglial tau pathology in the aged brain, facilitating communication among neuropathologists and researchers, and informing interpretation of clinical biomarkers and imaging studies that focus on tau-related indicators.